Analyte sensor

US12366548B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12366548-B2
Application numberUS-202318516661-A
CountryUS
Kind codeB2
Filing dateNov 21, 2023
Priority dateDec 30, 2015
Publication dateJul 22, 2025
Grant dateJul 22, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are devices for determining an analyte concentration. The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and an electronics unit operatively connected to the sensor. The electronics unit may be engaged with a housing that may secure the device to a host's skin. In this regard, in one embodiment, the housing may be attached to an adhesive patch that is fastened to the skin of the host.

First claim

Opening claim text (preview).

What is claimed is: 1. A device for measurement of a concentration of an analyte, the device comprising: a sensor having a sensing region and configured to generate a signal associated with the concentration of the analyte; and a sensing membrane located over the sensor, the sensing membrane comprising a biointerface layer positioned most distally to the sensing region such that its outermost domain contacts a biological fluid when inserted in vivo, wherein the biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterions forming repeating units in a polymer backbone; wherein the one or more zwitterions are derived from a monomer selected from the group consisting of: where Z is branched or straight chain alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl; R1 is H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R2, R3, and R4 are independently chosen from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and wherein two or more of R1, R2, R3, R4, and Z are substituted with a polymerization group; or wherein the one or more zwitterions are derived from a monomer selected from the group consisting of: where Z is branched or straight chain alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl; R1 is H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R2 and R3, are independently chosen from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein two or more of R1, R2, R3, and Z are substituted with a polymerization group; or wherein the one or more zwitterions are derived from a monomer selected from the group consisting of: where Z is branched or straight chain alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl; R1 is H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R2 and R3 are independently chosen from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein two or more of R1, R2, R3, and Z are substituted with a polymerization group. 2. The device of claim 1 , wherein the one or more zwitterions comprise a betaine compound or a derivative thereof. 3. The device of claim 1 , wherein the one or more zwitterions comprise at least one moiety selected from the group consisting of a carboxyl betaine, a sulfo betaine, a phosphor betaine, and derivatives thereof. 4. The device of claim 1 , wherein the polymerization group is selected from alkene, alkyne, epoxide, lactone, amine, hydroxyl, isocyanate, carboxylic acid, anhydride, silane, halide, aldehyde, and carbodiimide. 5. The device of claim 1 , wherein the one or more zwitterions is at least about 1 wt. % based on a total weight of the polymer. 6. The device of claim 1 , wherein the polyurethane and/or polyurea segments are from about 15 wt. % to about 75 wt. %, based on a total weight of the polymer. 7. The device of claim 1 , wherein the biointerface polymer further comprises at least one segment selected from the group consisting of epoxides, polyolefins, polysiloxanes, polyamide, polystyrene, polyacrylate, polyethers, polyesters, and polycarbonates. 8. The device of claim 1 , wherein the biointerface polymer further comprises a polyethylene oxide segment which is from about 5 wt. % to about 60 wt. %, based on a total weight of the biointerface polymer. 9. The device of claim 1 , wherein the biointerface polymer has a molecular weight of from about 10 kDa to about 500,000 kDa. 10. The device of claim 1 , wherein the biointerface polymer has a polydispersity index of from about 1.4 to about 3.5. 11. The device of claim 1 , wherein the biointerface layer has a contact angle of from about 20° to about 90°. 12. The device of claim 1 , wherein the one or more zwitterions are selected from the group consisting of cocamidopropyl betaine, oleamidopropyl betaine, octyl sulfobetaine, caprylyl sulfobetaine, lauryl sulfobetaine, myristyl sulfobetaine, palmityl sulfobetaine, stearyl sulfobetaine, betaine (trimethylglycine), octyl betaine, phosphatidylcholine, glycine betaine, poly (carboxybetaine), poly (sulfobetaine), and derivatives thereof. 13. The device of claim 1 , wherein the biointerface layer further comprises a pharmaceutical or biologic reagent. 14. The device of claim 1 , wherein the sensing membrane further comprises: an enzyme domain comprising an enzyme selected from the group consisting of glucose oxidase, glucose dehydrogenase, galactose oxidase, cholesterol oxidase, amino acid oxidase, alcohol oxidase, lactate oxidase, and uricase. 15. The device of claim 1 , wherein the sensor comprises an electrode. 16. The device of claim 1 , wherein the analyte is glucose. 17. The device of claim 1 , wherein the biointerface polymer does not comprise zwitterionic groups only at an end of a polymer chain. 18. The device of claim 1 , wherein the biointerface layer further comprises: a base polymer, wherein the base polymer comprises a surface modifying polymer covalently bonded to an internal region of the base polymer, wherein the surface modifying polymer comprises a polymer chain having both hydrophilic and hydrophobic regions and one or more zwitterionic compounds; and the base polymer is selected from silicone, epoxide, polyolefin, polystyrene, polyoxymethylene, polysiloxane, polyether, polyacrylic, polymethacrylic, polyester, polycarbonate, polyamide, poly (ether ketone), poly (ether imide), polyurethane, and polyurethane urea. 19. The device of claim 1 , wherein the device is configured for continuous measurement the analyte. 20. A device for the continuous measurement of a concentration of glucose, the device comprising: a sensor having an electrode including a sensing region and configured to generate a signal associated with the concentration of the glucose; and a sensing membrane located over the sensor, the sensing membrane comprising a biointerface layer positioned most distally to the sensing region such that its outermost domain contacts a biological fluid when inserted in vivo, wherein the biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterions forming repeating units in a polymer backbone; wherein the one or more zwitterions are derived from a monomer selected from the group consisting of: where Z is branched or straight chain alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl; R1 is H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R2, R3, and R4 are independently chosen from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and wherein two or more of R1, R2, R3, R4, and Z are substituted with a polymerization group; or wherein the one or more zwitterions are derived from a monomer selected from the group consisting of:

Assignees

Inventors

Classifications

  • Magnoliopsida (dicotyledons) · CPC title

  • invasive, e.g. introduced into the body by a catheter · CPC title

  • Insulins · CPC title

  • Medicinal preparations containing inorganic active ingredients · CPC title

  • Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12366548B2 cover?
Disclosed are devices for determining an analyte concentration. The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and an electronics unit operatively connected to the sensor. The electronics unit may be engaged with a housing that may secure the device to a host's skin. In this regard, in one embodiment, the housing may be attached to an…
Who is the assignee on this patent?
Dexcom Inc
What technology area does this patent fall under?
Primary CPC classification C12N11/089. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).